Biotech Dealmaker: Early-Stage Platforms And Tools Draw Capital As Full Buyouts Remain On The Sidelines This Week
Large drugmakers and specialized investors continued to favor targeted capability additions, asset purchases, and co-funding arrangements over outright buyouts of late-stage biotechs this week.